Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.1 million.

  • BioLineRx's Gains from Investment Securities fell 5706.37% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 2147.32%. This contributed to the annual value of -$19.0 million for FY2024, which is 27156.69% down from last year.
  • BioLineRx's Gains from Investment Securities amounted to -$1.1 million in Q3 2025, which was down 5706.37% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Gains from Investment Securities ranged from a high of $7.8 million in Q2 2023 and a low of -$8.4 million during Q2 2024
  • For the 3-year period, BioLineRx's Gains from Investment Securities averaged around -$1.4 million, with its median value being -$1.1 million (2025).
  • As far as peak fluctuations go, BioLineRx's Gains from Investment Securities crashed by 24618.42% in 2024, and later surged by 12262.83% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Gains from Investment Securities stood at -$2.9 million in 2023, then tumbled by 85.24% to -$5.4 million in 2024, then surged by 78.99% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, $1.9 million for Q2 2025, and -$8.3 million during Q1 2025.